Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Equity

v3.6.0.2
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
OPKO Uruguay Ltda.
EirGen Pharma Limited
Bio-Reference Laboratories, Inc.
Inspiro
OPKO Health Europe
OPKO Renal
Transition Therapeutics, Inc.
Common Stock
Common Stock
EirGen Pharma Limited
Common Stock
Bio-Reference Laboratories, Inc.
Common Stock
OPKO Renal
Common Stock
Transition Therapeutics, Inc.
Treasury
Treasury
OPKO Uruguay Ltda.
Treasury
Inspiro
Treasury
OPKO Health Europe
Additional Paid-In Capital
Additional Paid-In Capital
OPKO Uruguay Ltda.
Additional Paid-In Capital
EirGen Pharma Limited
Additional Paid-In Capital
Bio-Reference Laboratories, Inc.
Additional Paid-In Capital
Inspiro
Additional Paid-In Capital
OPKO Health Europe
Additional Paid-In Capital
OPKO Renal
Additional Paid-In Capital
Transition Therapeutics, Inc.
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Noncontrolling Interests
Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc.
Treasury
Xenetic Biosciences, Inc.
Additional Paid-In Capital
Beginning balance at Dec. 31, 2013 $ 872,979               $ 4,148         $ (7,362)       $ 1,379,383               $ 3,418 $ (503,177) $ (3,431)      
Beginning balance, shares (in shares) at Dec. 31, 2013                 414,818,195         (2,264,063)                                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                              
Equity-based compensation expense 14,737                                 14,737                          
Exercise of Common Stock options and warrants 12,928               $ 54                 12,874                          
Exercise of Common Stock options, shares (in shares)                 5,392,841                                            
Issuance of Common Stock in connection with acquisition 95,665 $ 159     $ 8,566   $ 21,155   $ 110     $ 22     $ 61 $ 3,250   95,555 $ 98     $ 5,316   $ 21,133              
Issuance of Common Stock in connection with acquisition (in shares)                 10,974,431     2,236,210     19,140 999,556                              
Net loss attributable to common shareholders (171,666)                                                   (171,666)        
Net loss attributable to noncontrolling interests (2,972)                                                     (2,972)      
Other comprehensive loss (15,810)                                                 (15,810)          
Ending balance at Dec. 31, 2014 835,741               $ 4,334         $ (4,051)       1,529,096               (12,392) (674,843) (6,403)      
Ending balance, shares (in shares) at Dec. 31, 2014                 433,421,677         (1,245,367)                                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                              
Equity-based compensation expense 26,074                                 26,074                          
Exercise of Common Stock options and warrants 25,920               $ 245                 25,675                          
Exercise of Common Stock options, shares (in shares)                 24,467,806                                            
Issuance of Common Stock in connection with acquisition $ 120,299   $ 33,596 $ 950,010     20,112   $ 81 $ 24 $ 766 $ 12           120,218   $ 33,572 $ 949,244     20,100              
Issuance of Common Stock in connection with acquisition (in shares)                 8,118,062 2,420,487 76,566,147 1,194,337                                      
Issuance of Treasury Stock in connection with Contingent Consideration           $ 1,812                     $ 406           $ 1,406                
Issuance of Treasury Stock in connection with Contingent Consideration (in shares)                                 125,000                            
Issuance of Treasury Stock for investment in Xenetic (in shares) 1,194,337                                                            
Net loss attributable to common shareholders $ (30,028)                                                   (30,028)        
Deconsolidation of SciVac 6,403                                                     6,403      
Net loss attributable to noncontrolling interests (1,400)                                                            
Other comprehensive loss (10,145)                                                 (10,145)          
Ending balance at Dec. 31, 2015 1,979,794               $ 5,462         $ (3,645)       2,705,385               (22,537) (704,871) $ 0      
Ending balance, shares (in shares) at Dec. 31, 2015                 546,188,516         (1,120,367)                                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                              
Equity-based compensation expense 42,693                                 42,693                          
Exercise of Common Stock options and warrants $ 8,608               $ 33                 8,575                          
Exercise of Common Stock options, shares (in shares) 1,836,572               3,292,753                                            
Issuance of Common Stock in connection with acquisition $ 583           $ 25,986 $ 58,530 $ 1     $ 26 $ 64         582           $ 25,960 $ 58,466            
Issuance of Common Stock in connection with acquisition (in shares)                 51,235     2,611,648 6,431,899                                    
Issuance of Treasury Stock in connection with Contingent Consideration           $ 313                     $ 127           $ 186                
Issuance of Treasury Stock in connection with Contingent Consideration (in shares)                                 39,145                            
Issuance of Treasury Stock for investment in Xenetic                                                         $ 4,856 $ 1,607 $ 3,249
Issuance of Treasury Stock for investment in Xenetic (in shares) 2,611,648                                                         494,462  
Net loss attributable to common shareholders $ (25,083)                                                   (25,083)        
Net loss attributable to noncontrolling interests 0                                                            
Other comprehensive loss (4,472)                                                 (4,472)          
Ending balance at Dec. 31, 2016 $ 2,091,808               $ 5,586         $ (1,911)       $ 2,845,096               $ (27,009) $ (729,954)        
Ending balance, shares (in shares) at Dec. 31, 2016                 558,576,051         (586,760)